NCT07025993 Effects of Muscle Energy Technique Versus Cervical and Scapulothoracic Stabilization Exercises in Upper Crossed Syndrome
| NCT ID | NCT07025993 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Upper Cross Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 34 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2025-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 34 participants in total. It began in 2025-03-01 with a primary completion date of 2025-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will be a randomized clinical trial and will be conducted in Younus Hospital, Tehsil headquarters hospital Daska, and Riphah Rehabilitation Clinic Lahore. Non-probability consecutive sampling will be used to collect the data. A sample size of 40 subjects with an age group between 18-65 years will be taken. Data will be collected from the patients having present complaints of Neck pain associated with upper cross syndrome. Outcome measures will be taken using the Numeric Rating Pain Scale (NRPS) for pain and the Neck disability index (NDI) for neck functional health and craniovertebral angle for posture. An informed consent will be taken. Subjects will be selected based on inclusion and exclusion criteria and will be equally divided into two groups by a random number generator table. Both Groups will receive Moist Hot Pack, Cervical segmental mobilizations, and Free Neck Exercises (AROMs), while Group A will receive Muscle energy technique(eccentric muscle energy technique for the cervical spine with Mets for upper trapezius, Suboccipitalis and pectoralis muscle), and Group B will receive cervical and scapulothoracic stabilization exercises(axial elongation exercise, craniocervical flexion, cervical extension and Cervico-scapulothoracic stabilization exercises). Outcome measures will be measured at baseline and after 4 weeks. Data analysis will be done by SPSS version 25.
Eligibility Criteria
Inclusion Criteria: * Both gender diagnosed with upper crossed syndrome * Patient having neck pain of 4 to 12 weeks * Pain reported on NRPS score ˃6/10 in the neck region * Subjects agree to sign the written consent form. Exclusion Criteria: * Exclusion criteria Patients were excluded if they were diagnosed with the following conditions for ˃6 months * Tuberculosis, carcinoma, heart disease, and osteoporosis * Neural disorders due to prolapsed intervertebral disc * Any trauma or localized infection in neck region * Upper motor neuron disease, cervical stenosis, and metabolic diseases in bone and joint * Hyper flexibility * Open sores * Ongoing radiotherapy, chemotherapy, steroid therapy, or anticoagulants * Psychiatric diseases such as phobia/obsession and depression * Allergy to hot pack
Contact & Investigator
Danish Hassan, PhD
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07025993 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Upper Cross Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07025993 currently recruiting?
Yes, NCT07025993 is actively recruiting participants. Contact the research team at shakil.urrehman@riphah.edu.pk for enrollment information.
Where is the NCT07025993 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07025993 clinical trial?
NCT07025993 is sponsored by Riphah International University. The principal investigator is Danish Hassan, PhD at Riphah International University. The trial plans to enroll 34 participants.